OLMA Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About OLMA Interactive Breakdown Better Bets vs. OLMA Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Olema Pharmaceuticals (OLMA)

    Market Price (9/5/2026): $10.74 | Market Cap: $1.1 BilSector: Health Care | Industry: Biotechnology

    Olema Pharmaceuticals (OLMA)

    Market Price (9/5/2026): $10.74
    Market Cap: $1.1 Bil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -41%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -46%, 3Y Excs Rtn is -56%

    Meaningful short interest
    Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.25, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15%

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -221 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23%

    High stock price volatility
    Vol 12M is 159%

    Key risks
    OLMA key risks include [1] binary Phase 3 results for its lead drug palazestrant, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -41%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -46%, 3Y Excs Rtn is -56%
    3 Meaningful short interest
    Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.25, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15%
    4 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    5 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -221 Mil
    6 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23%
    7 High stock price volatility
    Vol 12M is 159%
    8 Key risks
    OLMA key risks include [1] binary Phase 3 results for its lead drug palazestrant, Show more.

    OLMA in ETFs

    Weight = OLMA's share of each fund

    VTI0.00%
    ITOT0.00%
    IWM0.03%
    XBI0.26%
    IBB0.05%
    IWN0.04%
    VTWO0.03%
    DFAS0.02%
    +7 more covered ETFs

    Valuation & Metrics

    FYE: 12/31OLMA [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$2.2 Mil—
    FY 2027 Sales$8.2 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth263.9%13.1%
    EARNINGS
    LTM Net Income (GAAP) [3]$-204.6 Mil—
    FY 2026 Net Income (Non-GAAP)$-206.2 Mil—
    FY 2027 Net Income (Non-GAAP)$-237.7 Mil—
    FY 2027 Net Income Growth—18.6%
    FY 2026 EPS (Non-GAAP)$-2.39—
    FY 2027 EPS (Non-GAAP)$-2.66—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S498.61.7
    FY 2027 P/S137.0—
    FY 2026 P/E—7.7
    FY 2027 P/E——

    [1] OLMA forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Patients Enrolled in Phase 1b/2 Trial of palazestrant with ribociclib727082025Link
    Number of Phase 3 Clinical Trials for palazestrant (OP-1250)211032025Link
    Number of Phase 1 Clinical Studies for OP-3136111032025Link
    Employee Count9611072025Link

    Price Chart

    null
    Upcoming
    11/09/2026Earnings ReleaseRev: $1.0 Mil (E)
    EPS: $-0.60 (E)

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 9/1/2026

    Olema Pharmaceuticals (OLMA) stock has lost about 20% since 5/31/2026 because of the following key factors:

    1. Olema Pharmaceuticals (OLMA) reported a significantly widened net loss and missed analyst earnings estimates for fiscal Q2 2026. The company's net loss for the quarter ended June 30, 2026, increased to $63.2 million, up from $43.8 million in fiscal Q2 2025, driven by higher spending on clinical development and corporate activities for late-stage trials. Concurrently, Olema reported an Earnings Per Share (EPS) of -$0.61, which missed the consensus analyst estimate of -$0.55 by $0.06.

    2. The anticipated release of top-line data for the pivotal Phase 3 OPERA-01 trial of palazestrant was delayed to the first quarter of 2027. This extension of the timeline for a critical catalyst, which had been previously expected sooner, "resetting the near-term catalyst timeline" and triggered a "sharp single-day decline" in the stock.

    Show more
    Updated on 9/1/2026

    Olema Pharmaceuticals (OLMA) stock has lost about 20% since 5/31/2026 because of the following key factors:

    1. Olema Pharmaceuticals (OLMA) reported a significantly widened net loss and missed analyst earnings estimates for fiscal Q2 2026. The company's net loss for the quarter ended June 30, 2026, increased to $63.2 million, up from $43.8 million in fiscal Q2 2025, driven by higher spending on clinical development and corporate activities for late-stage trials. Concurrently, Olema reported an Earnings Per Share (EPS) of -$0.61, which missed the consensus analyst estimate of -$0.55 by $0.06.

    2. The anticipated release of top-line data for the pivotal Phase 3 OPERA-01 trial of palazestrant was delayed to the first quarter of 2027. This extension of the timeline for a critical catalyst, which had been previously expected sooner, "resetting the near-term catalyst timeline" and triggered a "sharp single-day decline" in the stock.

    3. Multiple analysts reduced their price targets for OLMA following the fiscal Q2 2026 results and the data delay. For example, JPMorgan Chase & Co. lowered its price target on Olema Oncology shares from $52.00 to $46.00, while Citigroup reduced its target from $62.00 to $59.00. HC Wainwright also decreased its price objective from $38.00 to $36.00.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -18.5% change in OLMA stock from 5/31/2026 to 9/4/2026 was primarily driven by a -1.6% change in the company's Shares Outstanding (Mil).
    (LTM values as of)53120269042026Change
    Stock Price ($)13.1910.75-18.5%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)103104-1.6%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    5/31/2026 to 9/4/2026
    ReturnCorrelation
    OLMA-18.5% 
    Market (SPY)1.8%22.7%
    Sector (XLV)14.7%20.5%

    Fundamental Drivers

    The -55.6% change in OLMA stock from 2/28/2026 to 9/4/2026 was primarily driven by a -17.9% change in the company's Shares Outstanding (Mil).
    (LTM values as of)22820269042026Change
    Stock Price ($)24.2010.75-55.6%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)86104-17.9%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    2/28/2026 to 9/4/2026
    ReturnCorrelation
    OLMA-55.6% 
    Market (SPY)12.6%29.8%
    Sector (XLV)7.5%20.6%

    Fundamental Drivers

    The 96.9% change in OLMA stock from 8/31/2025 to 9/4/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)83120259042026Change
    Stock Price ($)5.4610.7596.9%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)85104-18.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2025 to 9/4/2026
    ReturnCorrelation
    OLMA96.9% 
    Market (SPY)20.4%2.5%
    Sector (XLV)26.4%12.6%

    Fundamental Drivers

    The 5.9% change in OLMA stock from 8/31/2023 to 9/4/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)83120239042026Change
    Stock Price ($)10.1510.755.9%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)41104-61.0%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2023 to 9/4/2026
    ReturnCorrelation
    OLMA5.9% 
    Market (SPY)77.1%11.3%
    Sector (XLV)34.7%17.7%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    OLMA Return-81%-74%473%-58%329%-57%-78%
    Peers Return-8%-31%-24%-16%-9%-3%-64%
    S&P 500 Return27%-19%24%23%16%13%106%

    Monthly Win Rates [3]
    OLMA Win Rate25%33%75%25%58%22% 
    Peers Win Rate42%48%42%48%50%58% 
    S&P 500 Win Rate75%42%67%75%67%56% 

    Max Drawdowns [4]
    OLMA Max Drawdown-84%-78%-35%-66%-54%-69% 
    Peers Max Drawdown-59%-69%-66%-58%-69%-45% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: ARVN, VERU, ZYME, KPTI, CLDX.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 9/4/2026 (YTD)

    How Low Can It Go

    EventOLMAS&P 500
    2025 US Tariff Shock
      % Loss-40.7%-18.8%
      % Gain to Breakeven68.6%23.1%
      Time to Breakeven22 days79 days
    2023 SVB Regional Banking Crisis
      % Loss-32.8%-6.7%
      % Gain to Breakeven48.8%7.1%
      Time to Breakeven23 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-78.4%-24.5%
      % Gain to Breakeven362.3%32.4%
      Time to Breakeven413 days427 days

    Compare to ARVN, VERU, ZYME, KPTI, CLDX

    In The Past

    Olema Pharmaceuticals's stock fell -40.7% during the 2025 US Tariff Shock. Such a loss loss requires a 68.6% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventOLMAS&P 500
    2025 US Tariff Shock
      % Loss-40.7%-18.8%
      % Gain to Breakeven68.6%23.1%
      Time to Breakeven22 days79 days
    2023 SVB Regional Banking Crisis
      % Loss-32.8%-6.7%
      % Gain to Breakeven48.8%7.1%
      Time to Breakeven23 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-78.4%-24.5%
      % Gain to Breakeven362.3%32.4%
      Time to Breakeven413 days427 days

    Compare to ARVN, VERU, ZYME, KPTI, CLDX

    In The Past

    Olema Pharmaceuticals's stock fell -40.7% during the 2025 US Tariff Shock. Such a loss loss requires a 68.6% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Olema Pharmaceuticals (OLMA)

    Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for women's cancers. As a company in the clinical development phase, its core business revolves around advancing potential drug candidates through rigorous research and clinical trials with the goal of bringing new treatments to patients.

    The company's primary product candidate is OP-1250, an investigational drug designed to act as an estrogen receptor (ER) antagonist and a selective ER degrader. OP-1250 is currently in Phase 1/2 clinical trials, evaluating its potential as a treatment for recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

    Olema Pharmaceuticals serves the pharmaceutical and healthcare market, specifically targeting the oncology sector with a focus on women's cancers. Its eventual customers, upon successful development and regulatory approval, would be medical professionals, such as oncologists and other healthcare providers, who treat patients with advanced ER-positive breast cancer.

    AI Analysis | Feedback

    Here are 1-2 brief analogies for Olema Pharmaceuticals:

    • An early-stage Seagen for women's cancer treatments.

    • A developing Incyte specializing in women's cancer drugs.

    AI Analysis | Feedback

    • OP-1250: A lead drug candidate in Phase 1/2 clinical trials, developed as an estrogen receptor antagonist and selective ER degrader for the treatment of certain types of breast cancer.

    AI Analysis | Feedback

    Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company. As described, its lead product candidate, OP-1250, is currently in Phase 1/2 clinical trials. This means the company is primarily engaged in the discovery and development of therapies and has not yet commercialized any products.

    Therefore, Olema Pharmaceuticals does not currently have major customers that purchase its products or services. Its activities are focused on research and development to bring its drug candidates through clinical trials and regulatory approval.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Sean Bohen, M.D., Ph.D. President and Chief Executive Officer and Interim Principal Financial Officer
    Dr. Bohen was appointed President and Chief Executive Officer of Olema Pharmaceuticals in September 2020 and led the company's IPO in November 2020. A medical oncologist and biochemist by training, he previously served as Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca for approximately five years and led early development at Genentech for about 13 years.

    Shane Kovacs Former Chief Operating and Financial Officer
    Mr. Kovacs departed Olema Pharmaceuticals as Chief Operating and Financial Officer on January 30, 2026, to pursue new opportunities, but will continue in a consulting role with the company through August 1, 2026. He joined Olema in 2020 and contributed to guiding the company's lead product candidate, palazestrant, through late-stage clinical development, building the finance team, and establishing a strong capital position.

    David Myles, Ph.D. Chief Discovery and Non-Clinical Development Officer

    Naseem Zojwalla, M.D. Chief Medical Officer

    Shawnte Mitchell, J.D. Chief Legal Officer and Corporate Secretary

    AI Analysis | Feedback

    The key risks to Olema Pharmaceuticals (OLMA) are primarily associated with the inherent uncertainties of clinical-stage biopharmaceutical development, particularly concerning its lead product candidate, palazestrant (OP-1250).

    1. Clinical Trial Failure and Regulatory Approval Risk

    Olema Pharmaceuticals is a clinical-stage company with no products currently approved for commercial sale, making its value heavily dependent on the successful progression and eventual regulatory approval of its lead drug candidate, palazestrant. The company's future is significantly tied to the outcomes of its clinical trials, including the pivotal Phase 3 OPERA-01 study. A recent example highlighting this risk was the substantial decline in OLMA's stock (falling by -25.75% to -41%) following the disappointing results of a competitor's (Roche's giredestrant) similar drug in a late-stage Phase 3 clinical trial. This event raised concerns among investors about the entire class of selective estrogen receptor degraders (SERDs) that Olema is developing, even though palazestrant is a distinct molecule. Any setbacks in these trials, such as lack of efficacy, safety concerns, or failure to meet primary endpoints, could severely impact the company's prospects and stock price.

    2. Competition

    Olema operates in a competitive landscape, contending with other developers of oral SERDs and established endocrine therapies for breast cancer. The market share for palazestrant, if approved, will depend on its performance in pivotal trials, subsequent regulatory approvals, and its pricing compared to existing standards of care. The failure of a competitor's drug, as seen with Roche's giredestrant, underscores the intense competition and the potential for negative sentiment to impact the entire drug class, regardless of direct product differences. Olema must differentiate palazestrant in terms of efficacy and safety to succeed against both current treatments and other emerging therapies.

    3. Capital Needs and Operating Losses

    As a clinical-stage biopharmaceutical company without approved products or product revenue, Olema Pharmaceuticals consistently incurs significant net losses and requires substantial additional capital to fund its operations and ongoing research and development programs. Analysts anticipate widening losses as the company advances its lead drug candidate through late-stage trials. The intensive cash burn associated with drug development means that the company may need to secure additional financing, potentially through selling new shares, which could dilute the value for existing stockholders. Failure to raise necessary capital on favorable terms could force Olema to delay or discontinue critical development programs, directly impacting its future growth and valuation.

    AI Analysis | Feedback

    Major pharmaceutical companies are developing advanced oral selective estrogen receptor degrader (SERD) therapies for ER-positive, HER2-negative breast cancer that are significantly further along in clinical development than Olema's lead candidate, OP-1250. For instance, oral SERDs such as Arvinas/Pfizer's vepdegestrant, Eli Lilly's imoventant, and Roche's giredestrant are currently in Phase 3 clinical trials, while OP-1250 is in Phase 1/2. Should these competitors successfully complete their pivotal trials and gain regulatory approval, they could establish a dominant market position for oral SERDs, potentially limiting the future market opportunity and commercial viability for OP-1250.

    AI Analysis | Feedback

    Olema Pharmaceuticals (NASDAQ: OLMA) is developing OP-1250 (palazestrant), an estrogen receptor (ER) antagonist and selective ER degrader for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The addressable market for ER-positive, HER2-negative breast cancer is significant. In the United States, the total market size for ER+/HER2- breast cancer was estimated at USD 6,759 million in 2022 and is projected to grow through 2036. Globally, the HER2-negative breast cancer market was valued at approximately US$14.4 billion in 2024 and is projected to reach US$21.5 billion by 2030. Hormone receptor-positive/HER2-negative tumors constituted 57.25% of the HER2-negative breast cancer market size in 2025. Based on these figures, the global market for hormone receptor-positive/HER2-negative breast cancer was approximately USD 8.24 billion in 2025 (calculated as 57.25% of US$14.4 billion). OP-1250 specifically targets the recurrent, locally advanced, or metastatic forms within this broader ER+/HER2- breast cancer market. While a precise market size solely for this advanced stage sub-segment is not available, the figures for the overall ER+/HER2- breast cancer market indicate the significant scope of the disease area.

    AI Analysis | Feedback

    Olema Pharmaceuticals (OLMA), a clinical-stage biopharmaceutical company focused on women's cancers, is poised for potential revenue growth over the next two to three years primarily through the successful advancement of its lead product candidates and strategic collaborations. While the company is currently pre-revenue from product sales, anticipated revenue drivers include:
    1. Successful Advancement and Potential Regulatory Milestones for Palazestrant (OP-1250): The most significant driver of future revenue growth for Olema Pharmaceuticals is the successful progression of its lead product candidate, palazestrant (OP-1250), through pivotal Phase 3 clinical trials and towards potential regulatory approval. Top-line data from the Phase 3 OPERA-01 monotherapy study is anticipated in the second half of 2026, which is a critical catalyst for validating the drug's potential. Additionally, the Phase 3 OPERA-02 trial, evaluating palazestrant in combination with ribociclib, is actively enrolling patients. Positive outcomes from these trials and the subsequent submission of a New Drug Application (NDA) to the FDA for potential approval, with preparations for a possible commercial launch set for late 2027, are crucial for future product-based revenue.
    2. Strategic Partnerships and Collaborations: Olema Pharmaceuticals has demonstrated a strategy of forging significant collaborations to advance its pipeline. The company has a collaboration with Novartis for the Phase 3 OPERA-02 trial. Such strategic partnerships can provide substantial upfront payments, research funding, and milestone payments upon the achievement of specific clinical, regulatory, or commercial goals. These payments are a key source of revenue for clinical-stage biopharmaceutical companies like Olema. There is also mention of a potential collaboration with Pfizer and an ongoing Phase 1b/2 study with atirmociclib.
    3. Progression of OP-3136 and Pipeline Expansion: Beyond palazestrant, the advancement of other pipeline candidates, such as OP-3136 (a potent lysine acetyltransferase 6 (KAT6) inhibitor), represents another potential driver of future revenue. Initial clinical results for OP-3136 are expected in the second quarter of 2026. Successful development of additional assets can broaden the company's therapeutic portfolio, enhance its attractiveness for new partnerships, and potentially lead to new revenue streams through licensing agreements or future product sales.

    AI Analysis | Feedback

    Share Repurchases

    No information available regarding share repurchases made or authorized by Olema Pharmaceuticals over the last 3-5 years.

    Share Issuance

    • In November 2025, Olema Pharmaceuticals closed a public offering of 11,500,000 shares of common stock, including the full exercise of the underwriters' option, resulting in gross proceeds of approximately $218.5 million.
    • Olema Pharmaceuticals completed an equity private placement in December 2024, raising approximately $250 million.
    • In January 2025, the company entered into agreements to exchange approximately 6,070,000 shares of its common stock for pre-funded warrants with Bain Capital, Paradigm BioCapital, and BVF Partners.

    Inbound Investments

    • Olema Pharmaceuticals secured a $250 million private placement in December 2024 with new and existing institutional and accredited investors, including Bain Capital Life Sciences and other firms, to fund its clinical endeavors.
    • The company forged a significant collaboration with Novartis in December 2024 to advance its pivotal Phase 3 OPERA-02 trial, combining palazestrant with ribociclib.
    • In November 2025, Olema Pharmaceuticals announced a new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib.

    Outbound Investments

    No information available regarding outbound investments made by Olema Pharmaceuticals over the last 3-5 years.

    Capital Expenditures

    • Olema Pharmaceuticals' net loss of $162.5 million in 2025 was primarily driven by $178.7 million in operating expenses, reflecting increased research and development (R&D) and clinical trial spending.
    • GAAP R&D expenses increased to $157.7 million for the full year 2025, up from $124.5 million in 2024 and $86.1 million in 2023, mainly due to increased spending on clinical operations and development activities for palazestrant and OP-3136.
    • In the second quarter of 2025, GAAP R&D expenses included a one-time milestone payment of $10 million made to Aurigene.

    Peer Outperformance in Biotechnology

    OLMA has outperformed 59% of its 362 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
    Share of Biotechnology constituents that OLMA has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    72%
    of 456 industry peers · 69.3% return
    3Y
    55%
    of 403 industry peers · -15.2% return
    5Y
    59%
    of 362 industry peers · -63.5% return
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is OLMA's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 7 13.9%96.3%127.8% CAH 414% · MCK 351% · COR 179%
    Managed Health Care 8 33.2%1.7%3.3% OSCR 77% · HQY 48% · ELV 16%
    Health Care Services 20 21.0%52.1%-1.5% HIMS 238% · RDNT 134% · DGX 68%
    Health Care Facilities 24 1.8%4.9%-19.0% THC 249% · NHC 244% · ENSG 108%
    Health Care Equipment 50 -5.3%-4.8%-24.0% POCI 10775% · UFPT 318% · GKOS 200%
    Health Care Supplies 12 32.3%-14.4%-35.5% LNTH 272% · HAE 59% · MMSI 23%
    Pharmaceuticals 63 -0.9%0.6%-36.4% LQDA 2406% · INDV 1148% · ETON 1022%
    Life Sciences Tools & Services 109 2.4%-28.7%-73.9% SNWV 1688% · MEDP 203% · AXGN 178%
    Biotechnology ← 363 8.8%-25.7%-76.8% BRTX 73900% · DNTH 1558% · CELZ 1486%
    Health Care Technology 20 -25.0%-56.7%-78.6% SPOK 68% · HSTM -2% · VEEV -13%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Latest Trefis Analyses

    TitleDate
    0DASHBOARDS 
    1Olema Pharmaceuticals Earnings Notes12/27/2025
    Title
    0ARTICLES

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    SMMTSummit Therapeutics13.728.2%0.7%
    TARSTarsus Pharmaceuticals3.926.5%10.9%
    CNHCNH Industrial17.823.3%57.7%
    FRVOFervo Energy2.923.0%-50.3%
    BEBloom Energy72.620.0%191.0%
    EOSEEos Energy Enterprises1.319.0%-66.1%
    NXQuanex Building Products1.018.1%50.5%
    ODTXOdyssey Therapeutics0.918.1%75.2%
    SECZSecuritize1.118.0%-39.7%
    HUTHut 811.117.8%103.6%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    ADBTAdvasa0.2-93.3%-94.7%
    ALMSAlumis1.4-50.4%13.7%
    RAREUltragenyx Pharmaceutical1.6-40.3%-33.5%
    TRONTron0.7-28.8%19.4%
    CXMSprinklr1.4-27.6%-24.0%
    CRDOCredo Technology31.5-26.7%18.5%
    ENOVEnovis1.1-25.5%-30.3%
    GWREGuidewire Software13.7-21.1%-19.2%
    OXMOxford Industries0.5-19.4%-5.2%
    FICOFair Isaac21.1-19.2%-44.9%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    NXTTNext Technology0.8532.2%-12.8%
    MRNAModerna57.9170.2%393.6%
    CAPRCapricor Therapeutics0.5124.9%-67.4%
    QMCOQuantum0.5111.7%283.4%
    OABIOmniAb0.693.3%134.1%
    SENSSenseonics0.687.0%74.5%
    PURRHyperliquid Strategies1.582.6%242.1%
    HTFLHeartFlow4.279.9%67.8%
    STDNStandard Nuclear2.479.3%19.5%
    ABCLAbCellera Biologics3.575.0%234.2%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    ALMSAlumis1.4-60.1%13.7%
    IESCIES12.9-47.4%-17.1%
    LASRnLight2.3-46.9%6.8%
    CDNLCardinal Infrastructure0.6-41.8%50.7%
    RAREUltragenyx Pharmaceutical1.6-40.7%-33.5%
    AADXApplied Aerospace & Defense1.9-39.2%-32.0%
    AEVAAeva Technologies1.0-37.9%18.1%
    FTKFlotek Industries0.9-35.4%36.6%
    LINCLincoln Educational Services0.8-34.8%6.2%
    RXTRackspace Technology0.8-33.8%228.6%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    OLMAARVNVERUZYMEKPTICLDXMedian
    NameOlema Ph.Arvinas Veru ZymeworksKaryopha.Celldex . 
    Mkt Price10.759.392.6429.191.7939.6810.07
    Mkt Cap1.10.60.12.10.13.10.9
    Rev LTM0317037147019
    Op Inc LTM-221-18-28-155-82-326-119
    FCF LTM-165-209-26-121-65-242-143
    FCF 3Y Avg-128-275-27-86-100-185-114
    CFO LTM-165-207-26-119-65-236-142
    CFO 3Y Avg-128-273-27-83-100-181-114

    Growth & Margins

    OLMAARVNVERUZYMEKPTICLDXMedian
    NameOlema Ph.Arvinas Veru ZymeworksKaryopha.Celldex . 
    Rev Chg LTM--15.0%--69.8%6.8%-97.3%-42.4%
    Rev Chg 3Y Avg-81.2%--19.9%0.3%9.2%4.7%
    Rev Chg Q-1,014.7%--90.6%-11.9%-97.0%-51.2%
    QoQ Delta Rev Chg LTM-254.3%--54.3%-3.0%-81.8%-28.6%
    Op Inc Chg LTM-40.7%84.7%26.0%-87.9%28.5%-38.8%-6.4%
    Op Inc Chg 3Y Avg-29.9%43.3%32.1%-73.6%12.0%-39.1%-8.9%
    Op Mgn LTM--5.7%--418.8%-56.2%-206,220.3%-237.5%
    Op Mgn 3Y Avg--145.1%--225.9%-76.7%-70,746.9%-185.5%
    QoQ Delta Op Mgn LTM-278.1%--278.5%-0.4%-170,531.8%-139.5%
    CFO/Rev LTM--65.4%--321.4%-44.6%-149,092.4%-193.4%
    CFO/Rev 3Y Avg--134.1%--166.2%-69.7%-51,257.0%-150.2%
    FCF/Rev LTM--65.9%--325.1%-44.6%-153,231.0%-195.5%
    FCF/Rev 3Y Avg--135.2%--170.6%-69.7%-52,655.5%-152.9%

    Valuation

    OLMAARVNVERUZYMEKPTICLDXMedian
    NameOlema Ph.Arvinas Veru ZymeworksKaryopha.Celldex . 
    Mkt Cap1.10.60.12.10.13.10.9
    P/S-1.9-57.40.419,548.729.7
    P/Op Inc-5.1-33.6-2.2-13.7-0.6-9.5-7.3
    P/EBIT-5.1-33.6-2.2-14.3-0.3-9.5-7.3
    P/E-5.565.4-4.5-14.2-0.2-10.3-5.0
    P/CFO-6.8-2.9-2.3-17.9-0.8-13.1-4.9
    Total Yield-18.2%1.5%-22.4%-7.0%-433.9%-9.7%-14.0%
    Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
    FCF Yield 3Y Avg-20.9%-41.5%-198.6%-8.5%-721.6%-9.1%-31.2%
    D/E0.00.00.00.04.90.00.0
    Net D/E-0.4-0.9-0.4-0.13.7-0.2-0.3

    Returns

    OLMAARVNVERUZYMEKPTICLDXMedian
    NameOlema Ph.Arvinas Veru ZymeworksKaryopha.Celldex . 
    1M Rtn-7.2%11.8%13.3%24.2%-6.3%-3.4%4.2%
    3M Rtn4.3%26.5%-22.4%21.4%-80.3%38.6%12.8%
    6M Rtn-50.1%-31.0%6.9%21.2%-79.6%34.8%-12.0%
    12M Rtn69.3%23.4%-20.0%107.3%-73.4%74.2%46.3%
    3Y Rtn-15.2%-65.8%-75.8%298.2%-90.6%41.6%-40.5%
    1M Excs Rtn-9.0%8.1%14.2%26.1%-8.3%-4.6%1.7%
    3M Excs Rtn-0.3%22.0%-26.9%16.9%-84.8%34.1%8.3%
    6M Excs Rtn-64.6%-45.5%-7.6%6.7%-94.1%20.3%-26.6%
    12M Excs Rtn50.6%4.7%-38.7%88.6%-92.1%55.5%27.6%
    3Y Excs Rtn-55.7%-136.5%-147.0%226.2%-162.2%-27.9%-96.1%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/10/20265/12/20263/16/202611/10/20258/11/20255/13/20253/18/202511/12/20248/6/20245/8/20243/11/202411/7/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-67-58-50-46-48-35-37-38-33-34-30-23
    Operating Income-67-58-50-46-48-35-37-38-34-34-30-23
    Net Income-63-53-46-42-44-30-34-35-30-31-27-22
    EPS-0.61-0.52-0.51-0.49-0.51-0.36-0.40-0.60-0.54-0.56-0.48-0.48
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-221-201-178-165-157-142-142-136-121-109-105-101
    Operating Income TTM-221-202-179-165-157-143-142-136-122-110-105-102
    Net Income TTM-205-185-162-150-142-129-129-123-110-99-97-96
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-40.5%-66.5%-36.1%-22.1%-42.8%-1.4%-20.9%-61.4%-55.5%-16.1%-11.8%-0.5%
    Operating Income Growth-40.4%-66.3%-36.2%-21.9%-42.7%-1.6%-20.9%-61.2%-55.2%-16.0%-11.7%-0.5%
    Net Income Growth-44.3%-74.7%-37.2%-22.2%-44.1%1.9%-25.4%-60.7%-51.2%-9.5%-2.3%5.4%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash461505505329362393434215239249262277
    Total Debt444451122223
    Net Debt / (Cash)-457-501-501-324-357-392-433-213-237-247-259-274
    Cash Flows Quarterly            
    FCF from Operations-46-46-38-35-30-44-26-27-28-23-18-23
    Cash Flows TTM            
    FCF from Operations TTM-165-149-147-135-127-125-104-97-92-87-84-85
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-39.1%-36.8%-34.8%-34.3%-38.5%-30.5%-35.7%-38.8%-37.6%-42.1%-40.5%-33.4%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-32.2%-32.0%-31.1%-30.9%-31.6%-31.2%-34.6%-35.1%-34.1%-33.6%-35.0%-36.4%

    Segment Financials

    Assets by Segment
    $ Mil20252024202320222021
    Single segment533451277216296
    Total533451277216296


    Price Behavior

    Price Behavior
    Market Price$10.75 
    Market Cap ($ Bil)1.1 
    First Trading Date11/19/2020 
    Distance from 52W High-70.0% 
       50 Days200 Days
    DMA Price$11.29$17.72
    DMA Trendupdown
    Distance from DMA-4.7%-39.3%
     3M1YR
    Volatility56.5%158.6%
    Downside Capture122.13-3.47
    Upside Capture117.1858.42
    Correlation (SPY)26.4%2.7%
    OLMA Betas & Captures as of 8/31/2026

     1M2M3M6M1Y3Y
    Beta2.171.461.111.570.230.84
    Up Beta0.131.492.442.792.471.05
    Down Beta2.15-0.070.710.62-0.740.04
    Up Capture211%111%20%20%44%136%
    Bmk +ve Days10213268138427
    Stock +ve Days10183054114365
    Down Capture547%263%136%200%-40%107%
    Bmk -ve Days11213259113324
    Stock -ve Days11233372136378

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with OLMA
    OLMA69.6%158.6%0.83-
    Sector ETF (XLV)26.5%16.0%1.2812.5%
    Equity (SPY)19.7%12.8%1.132.6%
    Gold (GLD)24.6%29.2%0.755.8%
    Commodities (DBC)44.1%20.4%1.69-4.4%
    Real Estate (VNQ)9.1%13.6%0.3910.5%
    Bitcoin (BTCUSD)-26.9%43.8%-0.597.3%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with OLMA
    OLMA-18.3%107.7%0.26-
    Sector ETF (XLV)6.6%15.1%0.2521.7%
    Equity (SPY)12.8%17.2%0.5719.5%
    Gold (GLD)19.1%18.8%0.826.8%
    Commodities (DBC)10.7%19.5%0.43-1.1%
    Real Estate (VNQ)1.7%18.9%-0.0120.0%
    Bitcoin (BTCUSD)10.6%52.6%0.3814.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with OLMA
    OLMA-13.9%104.7%0.19-
    Sector ETF (XLV)10.8%16.7%0.5320.5%
    Equity (SPY)15.3%17.9%0.7219.0%
    Gold (GLD)12.4%16.3%0.627.1%
    Commodities (DBC)7.9%18.1%0.35-1.0%
    Real Estate (VNQ)4.8%20.7%0.1919.2%
    Bitcoin (BTCUSD)64.0%66.2%1.0412.3%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date8142026
    Short Interest: Shares Quantity15.8 Mil
    Short Interest: % Change Since 7312026-1.0%
    Average Daily Volume1.1 Mil
    Days-to-Cover Short Interest14.2 days
    Basic Shares Quantity104.5 Mil
    Short % of Basic Shares15.1%

    Earnings Returns History

    Updated 8/19/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/10/2026-12.6%-9.8% 
    5/12/2026-6.0%-13.2%-33.9%
    3/16/202612.8%-4.3%10.8%
    1/12/2026-3.1%-7.2%-17.9%
    11/10/20254.2%0.6%267.4%
    8/11/202516.2%26.0%70.9%
    5/13/2025-3.8%8.5%-13.2%
    3/18/2025-0.7%1.2%2.9%
    ...
    SUMMARY STATS   
    # Positive11109
    # Negative131414
    Median Positive6.8%5.5%21.1%
    Median Negative-6.6%-10.0%-19.3%
    Max Positive16.2%26.0%267.4%
    Max Negative-26.7%-36.7%-61.8%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/10/2026-12.6%-9.8% 
    5/12/2026-6.0%-13.2%-33.9%
    3/16/202612.8%-4.3%10.8%
    1/12/2026-3.1%-7.2%-17.9%
    11/10/20254.2%0.6%267.4%
    8/11/202516.2%26.0%70.9%
    5/13/2025-3.8%8.5%-13.2%
    3/18/2025-0.7%1.2%2.9%
    11/12/2024-0.5%-24.4%-41.8%
    8/6/2024-9.9%-10.1%-15.1%
    5/8/2024-9.3%-9.2%21.0%
    3/11/2024-6.6%-14.8%-15.8%
    11/7/20233.1%-4.5%-29.8%
    8/8/202312.1%14.3%21.1%
    5/9/2023-8.7%-12.8%-9.9%
    3/9/20233.5%1.3%-12.8%
    11/8/2022-5.1%2.2%-20.8%
    8/9/2022-26.7%-23.9%-21.2%
    5/9/20226.8%6.8%94.2%
    2/28/202215.0%-6.4%-3.0%
    11/10/20211.2%-5.5%-61.8%
    8/10/20214.9%4.1%12.8%
    5/11/202113.0%13.0%37.1%
    3/17/2021-10.2%-36.7%-27.2%
    SUMMARY STATS   
    # Positive11109
    # Negative131414
    Median Positive6.8%5.5%21.1%
    Median Negative-6.6%-10.0%-19.3%
    Max Positive16.2%26.0%267.4%
    Max Negative-26.7%-36.7%-61.8%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/10/202610-Q
    03/31/202605/12/202610-Q
    12/31/202503/16/202610-K
    09/30/202511/10/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/13/202510-Q
    12/31/202403/18/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/06/202410-Q
    03/31/202405/08/202410-Q
    12/31/202303/11/202410-K
    09/30/202311/07/202310-Q
    06/30/202308/08/202310-Q
    03/31/202305/09/202310-Q
    12/31/202203/09/202310-K
    09/30/202211/08/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/10/202610-Q
    03/31/202605/12/202610-Q
    12/31/202503/16/202610-K
    09/30/202511/10/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/13/202510-Q
    12/31/202403/18/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/06/202410-Q
    03/31/202405/08/202410-Q
    12/31/202303/11/202410-K
    09/30/202311/07/202310-Q
    06/30/202308/08/202310-Q
    03/31/202305/09/202310-Q
    12/31/202203/09/202310-K
    09/30/202211/08/202210-Q
    06/30/202208/09/202210-Q
    03/31/202205/09/202210-Q
    12/31/202102/28/202210-K
    09/30/202111/10/202110-Q
    06/30/202108/10/202110-Q
    03/31/202105/11/202110-Q
    12/31/202003/17/202110-K
    09/30/202011/19/2020424B4

    Insider Activity

    Updated 9/2/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Harmon, CyrusDirectSell727202611.7112,500146,4258,232,248Form
    2Harmon, CyrusDirectSell727202611.5812,500144,7388,282,111Form
    3Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202624.2524,767600,6005,650Form
    4Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202624.69233  Form
    5Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202623.0115,000  Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Harmon, CyrusDirectSell727202611.7112,500146,4258,232,248Form
    2Harmon, CyrusDirectSell727202611.5812,500144,7388,282,111Form
    3Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202624.2524,767600,6005,650Form
    4Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202624.69233  Form
    5Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202623.0115,000  Form
    6Harmon, CyrusDirectSell121202626.8810,000268,80019,562,458Form
    7Harmon, CyrusDirectSell116202629.123,489101,60021,483,862Form
    8Kovacs, Shane William CharlesCH. OPERATING & FINANCIAL OFF.DirectSell115202628.73100,0002,873,0004,014,357Form
    9Kovacs, Shane William CharlesCH. OPERATING & FINANCIAL OFF.DirectSell115202628.013,822107,0546,714,753Form
    10Myles, David CCH. DISCOV. & NON-CLIN DEV OFFDirectSell114202628.8750,0001,443,65115,671,151Form
    11Myles, David CCH. DISCOV. & NON-CLIN DEV OFFDirectSell114202627.6050,0001,380,17814,982,136Form
    12Myles, David CCH. DISCOV. & NON-CLIN DEV OFFSee FootnoteSell114202628.3410,000283,4004,104,936Form
    13Harmon, CyrusDirectSell1229202528.532,88182,19521,148,119Form
    14Zojwalla, NaseemChief Medical OfficerDirectSell1223202527.6699,5092,752,419124,138Form
    15Zojwalla, NaseemChief Medical OfficerDirectSell1223202528.04100,0002,804,0001,514,076Form
    16Clark, Ian TDirectSell1223202529.73264,800  Form
    17Myles, David CCH. DISCOV. & NON-CLIN DEV OFFDirectSell1223202530.4651,0001,553,54416,811,199Form
    18Zojwalla, NaseemChief Medical OfficerDirectSell1223202528.2070,0001,973,7292,932,313Form
    19Harmon, CyrusDirectSell91820258.3310,00083,3006,198,686Form
    20Harmon, CyrusSee FootnoteSell91820258.323,08625,676973,673Form
    21Harmon, CyrusDirectSell91820258.0410,00080,4006,063,286Form
    22Harmon, CyrusSee FootnoteSell91820258.081,91415,465970,521Form

    Investor Activity (13F)

    Updated Sep 5, 2026
    13F holdings as of Mar 31, 2026 (Q1 2026)

    Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Defilade Capital Management, L.P.$22.4 Mil3.1%31ADD +21.9%13F
    Cormorant Asset Management, LP$58.1 Mil2.9%46ADD +41.8%13F
    BVF Inc/Il$79.0 Mil2.5%41Hold13F
    Paradigm Biocapital Advisors LP$119.6 Mil2.4%35ADD +6.3%13F
    Lightspeed Management Company, L.L.C.$20.2 Mil2.0%8TRIM -29.8%13F
    First Turn Management, LLC$11.5 Mil1.3%33ADD +24.4%13F
    Vivo Capital, LLC$10.0 Mil0.8%46Hold13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Cormorant Asset Management, LP$58.1 Mil2.9%46ADD +41.8%13F
    First Turn Management, LLC$11.5 Mil1.3%33ADD +24.4%13F
    Defilade Capital Management, L.P.$22.4 Mil3.1%31ADD +21.9%13F
    Paradigm Biocapital Advisors LP$119.6 Mil2.4%35ADD +6.3%13F
    Active ManagerValue% of PortfolioTotal PositionsQoQAs OfFiling
    Catalio Capital Management, LP$6.7 Mil1.2%45ExitedDec 31, 202513F
    Lightspeed Management Company, L.L.C.$20.2 Mil2.0%8TRIM -29.8%Mar 31, 202613F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Paradigm Biocapital Advisors LP$119.6 Mil2.4%35ADD +6.3%13F
    BVF Inc/Il$79.0 Mil2.5%41Hold13F
    Cormorant Asset Management, LP$58.1 Mil2.9%46ADD +41.8%13F
    Defilade Capital Management, L.P.$22.4 Mil3.1%31ADD +21.9%13F
    Lightspeed Management Company, L.L.C.$20.2 Mil2.0%8TRIM -29.8%13F
    First Turn Management, LLC$11.5 Mil1.3%33ADD +24.4%13F
    Vivo Capital, LLC$10.0 Mil0.8%46Hold13F

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 9/4/2026